Tucker Asset Management LLC Sells 994 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Tucker Asset Management LLC decreased its position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 3.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 27,956 shares of the company’s stock after selling 994 shares during the period. Amphastar Pharmaceuticals comprises 0.4% of Tucker Asset Management LLC’s holdings, making the stock its 18th largest holding. Tucker Asset Management LLC owned approximately 0.06% of Amphastar Pharmaceuticals worth $1,729,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in AMPH. McGlone Suttner Wealth Management Inc. acquired a new stake in shares of Amphastar Pharmaceuticals in the 4th quarter valued at approximately $28,000. Principal Securities Inc. acquired a new stake in Amphastar Pharmaceuticals in the fourth quarter valued at approximately $34,000. Quadrant Capital Group LLC grew its stake in shares of Amphastar Pharmaceuticals by 27.8% during the fourth quarter. Quadrant Capital Group LLC now owns 1,026 shares of the company’s stock worth $63,000 after buying an additional 223 shares during the last quarter. Covestor Ltd increased its holdings in shares of Amphastar Pharmaceuticals by 859.0% during the third quarter. Covestor Ltd now owns 1,966 shares of the company’s stock worth $90,000 after buying an additional 1,761 shares in the last quarter. Finally, Nisa Investment Advisors LLC lifted its stake in shares of Amphastar Pharmaceuticals by 115.0% in the 4th quarter. Nisa Investment Advisors LLC now owns 2,430 shares of the company’s stock valued at $150,000 after acquiring an additional 1,300 shares during the last quarter. 65.09% of the stock is owned by institutional investors.

Insider Transactions at Amphastar Pharmaceuticals

In related news, Director Floyd F. Petersen sold 3,000 shares of the business’s stock in a transaction on Monday, June 10th. The shares were sold at an average price of $41.40, for a total value of $124,200.00. Following the transaction, the director now owns 78,409 shares in the company, valued at $3,246,132.60. The transaction was disclosed in a document filed with the SEC, which is available through this link. Insiders sold a total of 4,500 shares of company stock worth $188,075 over the last three months. 27.10% of the stock is owned by company insiders.

Amphastar Pharmaceuticals Trading Down 0.3 %

Shares of AMPH stock traded down $0.14 on Friday, hitting $40.49. The company had a trading volume of 274,075 shares, compared to its average volume of 315,562. Amphastar Pharmaceuticals, Inc. has a twelve month low of $38.43 and a twelve month high of $67.66. The company has a debt-to-equity ratio of 0.88, a quick ratio of 1.72 and a current ratio of 2.18. The firm has a market cap of $1.98 billion, a P/E ratio of 14.01, a P/E/G ratio of 0.83 and a beta of 0.82. The stock’s 50-day moving average is $41.60 and its two-hundred day moving average is $49.07.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last released its earnings results on Wednesday, May 8th. The company reported $0.93 earnings per share for the quarter, beating analysts’ consensus estimates of $0.73 by $0.20. The business had revenue of $171.84 million during the quarter, compared to the consensus estimate of $171.13 million. Amphastar Pharmaceuticals had a net margin of 22.88% and a return on equity of 29.17%. On average, equities research analysts anticipate that Amphastar Pharmaceuticals, Inc. will post 3.6 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on AMPH. JPMorgan Chase & Co. initiated coverage on Amphastar Pharmaceuticals in a report on Tuesday, March 5th. They issued an “overweight” rating and a $60.00 target price for the company. Needham & Company LLC reiterated a “hold” rating on shares of Amphastar Pharmaceuticals in a report on Wednesday, May 22nd. Finally, StockNews.com raised shares of Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, May 13th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $66.00.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.